Administration of a live, attenuated vaccine within  weeks before Cycle , Day 
Patients are ineligible if administration of a live, attenuated vaccine within  weeks before randomization
Administration of live vaccine within  weeks prior to study entry
Treatment with a live, attenuated vaccine within  weeks before initiation of study treatment, or anticipation of need for such a vaccine during the course of the study
Administration of a live, attenuated vaccine within  days prior to randomization or anticipation that such vaccine will be required during the study. Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within  days prior to randomization, during treatment or within  months following the last dose of atezolizumab/placebo.
Administration of a live attenuated vaccine within  weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study
Administration of a live, attenuated vaccine within  weeks before Cycle  Day 
Treatment with a live, attenuated vaccine within  weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study
Treatment with therapeutic oral or intravenous (IV) antibiotics; or with a live, attenuated vaccine; or systemic immunosuppressive medication
Administration of a live, attenuated vaccine within  weeks prior to Cycle  Day  or at any time during the study and for at least  months after the last dose of study drug
Receipt of a live, attenuated vaccine within  weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study
Administration of a live vaccine within  weeks prior to study entry
Receipt of a live, attenuated vaccine within  weeks prior to randomisation or anticipation that a live, attenuated vaccine will be required during atezolizumab/placebo treatment or within  months after the last dose of atezolizumab/placebo
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live attenuated vaccine will be required during the study
Any live, attenuated vaccine within  days prior to the first day of treatment or during study treatment, or unwillingness to avoid live, attenuated vaccines within  days following the last dose of atezolizumab
Administration of a live vaccine within  weeks prior to start of protocol therapy
Administration of a live, attenuated vaccine within  weeks for first study treatment
Live, attenuated vaccine within  days prior to the first dose of protocol therapy
Patients who have received a live attenuated vaccine =<  days prior to registration are not eligible
Has received a live attenuated vaccine within  days prior to enrolling in the study.
Administration of a live, attenuated vaccine within  weeks prior to enrollment or anticipation that such a live attenuated vaccine will be required during the study
Received a live attenuated vaccine within  days of first study dose, unable to take oral medications
Administration of a live, attenuated vaccine within  weeks prior to randomization or anticipation that such vaccine will be required during the study\r\n* Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within  weeks prior to randomization, during treatment or within  months following the last dose of atezolizumab/placebo
Live, attenuated vaccine within  days prior to day  of protocol therapy
Administration of a live, attenuated vaccine within  weeks of Cycle , Day  or anticipation that such a live attenuated vaccine will be required during the study
Patients who receive a live attenuated vaccine =<  days prior to registration are not eligible
Administration of a live, attenuated vaccine within  weeks of the start of treatment or anticipation that such a live, attenuated vaccine will be required during the study
Administration of a live, attenuated vaccine within  weeks before first dosing or during the study.
Has received live, attenuated vaccine within  days prior to Study Day 
Patient who requires live vaccine administration
Subject has received a live, attenuated vaccine within  days prior to Cycle  Day ;
Receipt of a live, attenuated vaccine within  weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study
Has received live, attenuated vaccine within  days prior to Study Day 
Treatment with a live vaccine or a live, attenuated vaccine (e.g., nasal spray of live attenuated influenza vaccine or FluMist) within  weeks prior to initiation of study drug or anticipation that such treatment will be required during the study or within  months after the final dose of study drug
Treatment with a live, attenuated vaccine within  weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study, or up to  months following the anticipated last dose of atezolizumab
Administration of a live, attenuated vaccine within  weeks prior to enrollment
Live attenuated vaccine within  weeks of study drug
Administration of a live, attenuated vaccine within  weeks before Cycle , Day  or anticipation that such a live, attenuated vaccine will be required during the study
Administration of attenuated vaccine within  weeks before enrollment
Vaccination with a live virus vaccine or live attenuated vaccine within  days prior to DC
Administration of a live, attenuated vaccine within  weeks prior to randomization
Administration of a live, attenuated vaccine within  weeks before Cycle , Day 
Administration of a live, attenuated vaccine within  weeks before Cycle  Day  Exclusion Criteria Unique to Cobimetinib:
Administration of a live, attenuated vaccine within  days before first dose of study treatment.
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study
Administration of a live, attenuated vaccine within  weeks before Cycle , Day  or anticipation that such a live attenuated vaccine will be required during the study
Administration of a live/attenuated vaccine within  weeks prior to the first dose of study treatment, within  months following the administration of the last dose of study drug, or anticipation that such a live/attenuated vaccine will be required during the study
Administration of live, attenuated vaccine within  weeks before the start of treatment (day ) and throughout the study
Administration of a live, attenuated vaccine within  weeks before cycle , day  or anticipation that such a live, attenuated vaccine will be required during the study
Administration of live, attenuated vaccine within  weeks before the start of treatment (day ) and throughout the study
Any plan to receive a live attenuated vaccine during study treatment
Administration of a live, attenuated vaccine within  weeks before Cycle , Day  or anticipation that such a live attenuated vaccine will be required during the study
Administration of a live, attenuated vaccine within  weeks before Cycle , Day  or anticipation that such a live attenuated vaccine will be required during the study
Administration of a live, attenuated vaccine within  weeks for first study treatment
Administration of a live, attenuated vaccine within  weeks before Cycle , Day  or anticipation that such a live attenuated vaccine will be required during the study
Live attenuated vaccine within  weeks prior to first day of study treatment
Receipt of a live, attenuated vaccine within  weeks prior to initiation of study drug (cycle , day  [CD]) or anticipation that such a live, attenuated vaccine will be required during the study
Administration of a live, attenuated vaccine within  days before Day  or anticipation that such a live attenuated vaccine will be required during the study
Administration of a live, attenuated vaccine within  weeks before Cycle , Day 
